share_log

科濟藥業-B：自願公告 - 於2024年美國臨床腫瘤學會年會胃腸腫瘤研討會上呈列的CT041研究成果更新

CARSGEN-B: VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT041 AT 2024 ASCO GI MEETING

香港交易所 ·  Jan 19 08:00
Summary by Futu AI
科济药业-B（股份代號：2171）於2024年美國臨床腫瘤學會年會胃腸腫瘤研討會（ASCO GI）上發表了其CAR-T細胞候選產品satri-cel（研發代號：CT041）的1b期臨床試驗結果更新。該研究針對Claudin18.2陽性的晚期胃癌╱食管胃結合部腺癌（GC/GEJ）或胰腺癌（PC）患者，評估satri-cel的安全性和有效性。研究結果顯示，satri-cel整體安全性良好，未觀察到劑量限制性毒性（DLT）或治療相關死亡，並在某些患者中達到了完全緩解。目前，2期臨床試驗正在進行中，並已確定600×106個細胞為2期推薦劑量（RP2D）。科济药业表示，satri-cel作為首個自體Claudin18.2 CAR T細胞療法，在多重治療後的晚期GC/GEJ和PC患者中展現出前景。公司致力於成為全球生物製藥的領導者，為全球癌症患者帶來創新和差異化的細胞療法。
科济药业-B（股份代號：2171）於2024年美國臨床腫瘤學會年會胃腸腫瘤研討會（ASCO GI）上發表了其CAR-T細胞候選產品satri-cel（研發代號：CT041）的1b期臨床試驗結果更新。該研究針對Claudin18.2陽性的晚期胃癌╱食管胃結合部腺癌（GC/GEJ）或胰腺癌（PC）患者，評估satri-cel的安全性和有效性。研究結果顯示，satri-cel整體安全性良好，未觀察到劑量限制性毒性（DLT）或治療相關死亡，並在某些患者中達到了完全緩解。目前，2期臨床試驗正在進行中，並已確定600×106個細胞為2期推薦劑量（RP2D）。科济药业表示，satri-cel作為首個自體Claudin18.2 CAR T細胞療法，在多重治療後的晚期GC/GEJ和PC患者中展現出前景。公司致力於成為全球生物製藥的領導者，為全球癌症患者帶來創新和差異化的細胞療法。
Kozai Pharmaceuticals-B (stock code: 2171) announced a Phase 1b clinical trial update of its CAR-T cell candidate product satri-cel (R&D code: CT041) at the 2024 American Society of Clinical Oncology Annual Conference on Gastrointestinal Oncology (ASCO GI). The study evaluated the safety and efficacy of satri-cel in patients with Claudin18.2-positive late-stage gastric/gastroesophageal combined prostate cancer (GC/GEJ) or pancreatic cancer (PC). The results showed that satri-cel had good overall safety, with no dose-limiting toxicity (DLT) or treatment-related death observed, and complete relief was achieved in some patients. Currently, a 2-phase clinical trial is underway and 600×106 cells have been identified as the Phase 2 Recommended Dose (RP2D). As the first autologous Claudin18.2 CAR T cell therapy, satri-cel shows promise in patients with late GC/GEJ and PC after multiple treatments, said Kozai Pharmaceuticals. The company is committed to being a global leader in biopharmaceuticals, bringing innovative and differentiated cell therapies to cancer patients worldwide.
Kozai Pharmaceuticals-B (stock code: 2171) announced a Phase 1b clinical trial update of its CAR-T cell candidate product satri-cel (R&D code: CT041) at the 2024 American Society of Clinical Oncology Annual Conference on Gastrointestinal Oncology (ASCO GI). The study evaluated the safety and efficacy of satri-cel in patients with Claudin18.2-positive late-stage gastric/gastroesophageal combined prostate cancer (GC/GEJ) or pancreatic cancer (PC). The results showed that satri-cel had good overall safety, with no dose-limiting toxicity (DLT) or treatment-related death observed, and complete relief was achieved in some patients. Currently, a 2-phase clinical trial is underway and 600×106 cells have been identified as the Phase 2 Recommended Dose (RP2D). As the first autologous Claudin18.2 CAR T cell therapy, satri-cel shows promise in patients with late GC/GEJ and PC after multiple treatments, said Kozai Pharmaceuticals. The company is committed to being a global leader in biopharmaceuticals, bringing innovative and differentiated cell therapies to cancer patients worldwide.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.